Research Topics
| Lauren KruppSummaryAffiliation: State University of New York Country: USA Publications
Research Grants
|
Detail Information
Publications
Multiple sclerosis-associated fatigueLauren B Krupp
Stony Brook University Medical Center, Department of Neurology, Stony Brook, NY 11794 8121, USA
Expert Rev Neurother 10:1437-47. 2010..Nonetheless, further research and the development of more targeted therapies are needed to improve the management of fatigue...
Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trialL B Krupp
Department of Neurology, Stony Brook University Medical Center, Stony Brook, NY 11794 8121, USA
Neurology 60:1923-30. 2003..To determine whether post Lyme syndrome (PLS) is antibiotic responsive...
High-dose cyclophosphamide for moderate to severe refractory multiple sclerosisDouglas E Gladstone
Department of Medicine, State University of New York at Stony Brook, USA
Arch Neurol 63:1388-93. 2006..High-dose cyclophosphamide is active in immune-mediated illnesses...
Managing MS. While a cure is sought, people with MS can help themselvesLauren Krupp
Pediatric MS Center, Stony Brook University Medical Center, Long Island, New York, USA
Health News 8:4. 2002
Longitudinal neuropsychological assessment in pediatric multiple sclerosisWilliam S MacAllister
Department of Medicine, School of Neurology, State University of New York at Stony Brook, Stony Brook, NY, USA
Dev Neuropsychol 32:625-44. 2007..The number of interim relapses (i.e., relapses occurring between baseline assessment and re-evaluation) showed a modest relationship to changes in cognitive function, but this did not reach statistical significance...
Perceived cognitive dysfunction and observed neuropsychological performance: longitudinal relation in persons with multiple sclerosisChristopher Christodoulou
Department of Neurology, State University of New York at Stony Brook, Stony Brook, New York 11794 8121, USA
J Int Neuropsychol Soc 11:614-9. 2005..Patients accurately perceived some changes in their level of cognitive dysfunction, though they were insensitive to the degree of their current dysfunction. Possible explanations of this pattern of results are discussed...
Multiple sclerosis-related fatigueWilliam S MacAllister
National Pediatric Multiple Sclerosis Center, State University of New York at Stony Brook, Stony Brook, NY 11794-8121, USA
Phys Med Rehabil Clin N Am 16:483-502. 2005..The first-line agents include amantadine for mild fatigue and modafinil for more severe cases. Second-line agents include pemoline and antidepressant medications. Other pharmacologic agents have also shown some promise...
Fatigue in multiple sclerosis: definition, pathophysiology and treatmentLauren B Krupp
Department of Neurology, State University of New York at Stony Brook, New York, New York 11794, USA
CNS Drugs 17:225-34. 2003..Both medications have been studied with positive results in controlled clinical trials. Additional research towards measurement and pathogenesis of fatigue will hopefully lead to improved therapies...
Fatigue in Parkinson's disease: a reviewJoseph H Friedman
NeuroHealth, Warwick, Rhode Island 02886, USA
Mov Disord 22:297-308. 2007..This article reviews what is known about the symptom, putting it into the context of fatigue in other disorders, and outlines a program for developing better understanding and therapy...
Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?Christopher Christodoulou
Department of Neurology, State University of New York at Stony Brook, Stony Brook, New York 11794 8121, USA
CNS Drugs 22:87-97. 2008..On the whole, to date the research on AChEIs in MS must be considered preliminary, and it is premature to recommend the clinical use of this class of medications at the present time...
Effects of donepezil on memory and cognition in multiple sclerosisChristopher Christodoulou
Department of Neurology, State University of New York, Stony Brook, HSC T12 020, 11794 8121, USA
J Neurol Sci 245:127-36. 2006..Replication of results in a larger multi-center investigation is warranted in order to more definitively assess the efficacy of this intervention...
Research Grants
- NEUROBEHAVIORAL SYNDROME IN LATE BURGDORFERI INFECTIONLauren Krupp; Fiscal Year: 2001..2. To determine the pathogenesis for neurobehavioral deficits in chronic Lyme disease. 3. To identify the clinical and laboratory factors which predict health outcome in chronic Lyme disease. ..
- Assessment of Cognitive Dysfunction in MSLauren Krupp; Fiscal Year: 2000..abstract_text> ..
- Interventions to Improve Memory in MS PatientsLauren Krupp; Fiscal Year: 2000..It is hypothesized a greater proportion of MS patients treated with donepezil will show improvement in verbal memory that those treated with placebo. ..
- TREATMENT OF DESERT STORM SYNDROMELauren Krupp; Fiscal Year: 2001..Learning and memory measures include the Selective Reminding Test (SRT), and WMS-R Logical memory Test, and the Continuous Visual Memory test (CVMT). ..
- CHRONIC FATIGUE IN POST LYME DISEASELauren Krupp; Fiscal Year: 2001..If no difference between antibiotic and placebo therapy is observed, this will be important objective data suggesting the inappropriateness of repeated courses of antibiotic therapy for PLS. ..
- Central Fatigue and Related Cognitive FunctionLauren Krupp; Fiscal Year: 2001..Using our model, we propose to define cognitive fatigue in two conditions in which cognitive dysfunction is a prominent feature: subjects with MS and healthy sleep-deprived subjects. ..
- Cognitive Functioning Following Sleep DeprivationLauren Krupp; Fiscal Year: 2000..abstract_text> ..
- INTERVENTIONS TO IMPROVE MEMORY IN PATIENTS WITH MSLauren Krupp; Fiscal Year: 2001..The investigators will also measure secondary outcomes assessing other areas of cognitive dysfunction (i.e., nonverbal memory, conceptual thinking, processing speed) which may improve with intervention. ..
- CNS INVASION IN EARLY B BURGDORFERI INFECTIONLauren Krupp; Fiscal Year: 1999..The study parameters will include clinical features, immune response, cerebrospinal fluid changes, neurocognitive disturbances, and psychosocial aspects of the disease. ..
- INTERVENTIONS TO IMPROVE MEMORY IN PATIENTS WITH MSLauren Krupp; Fiscal Year: 2006..Specific Aim 2: To examine the relationship of treatment response to baseline subject characteristics, such as baseline neuropsychological performance, and MS subtype. ..
